The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis

Journal of Bone and Mineral Research

Volumn 18, Issue 1, 2003, Pages 9-17

  Orwoll, E S ^a   Scheele, W H ^b   Paul, S ^b   Adami, S ^c   Syversen, U ^d   Diez Perez, A ^e   Kaufman, J M ^f   Clancy, A D ^b   Gaich, G A ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e HOSPITAL DEL MAR   (Spain)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bone density; Drug therapy; Men; Osteoporosis; Teriparatide

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFECT; FEMUR NECK; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; MALE; MINERAL METABOLISM; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; OSTEOSARCOMA; RADIUS; RANDOMIZED CONTROLLED TRIAL; RAT; SPINE; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOSARCOMA; RATS; RATS, INBRED F344; TERIPARATIDE;

EID: 0037214255     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.1.9     Document Type: Article

References (28)

1. Orwoll ES 1998 Osteoporosis in men. Endocrinol Metab Clin North Am 27:349-367.
2. Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B, Sedrine WB, Calvo G, Devogelaer JP, Fuchs V, Kreutz G, Nilsson P, Pols H, Ringe J, Van Haelst L, Reginster JY 2000 Background for studies on the treatment of male osteoporosis: State of the art. Ann Rheum Dis 59:765-772.
3. Gullberg B, Johnell O, Kanis JA 1997 World-wide projections for hip fracture. Osteoporos Int 7:407-413.
4. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III 1992 Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227.
5. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ 1996 The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 11: 1010-1018.
6. Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutte HE, Birkenhager JC, Pols HA 1997 Vertebral deformities and functional impairment in men and women. J Bone Miner Res 12:152-157.
7. Melton LJ III, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL 1999 Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214-221.
8. Orwoll ES, Klein RF 1995 Osteoporosis in men. Endocrinol Rev 16:-87-116.
9. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610.
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
11. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM 1986 Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1:377-381.
12. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076.
13. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
14. Satterwhite J, Melnick K, O'Brien L, Myers S, Heathman M 2001 Men and postmenopausal women with osteoporosis have similar lumbar spine bone mineral density responses to recombinant human parathyroid hormone (1-34) despite pharmacokinetic and biochemical marker differences. Arthritis Rheum 44(Suppl):S255.
15. Rosen CJ, Bilezikian JP 2001 Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957-964.
16. Delmas PD 2000 Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11(Suppl 6):S66-S76.
17. Cosman F, Nieves J, Woelfert L, Gordon S, Shen V, Lindsay R 1998 Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. J Clin Endocrinol Metab 83:788-790.
18. Fukayama S, Tashjian AH Jr 1989 Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology 125: 1789-1794.
19. Fukayama S, Tashjian AH Jr 1989 Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein. Endocrinology 124: 397-401.
20. Mosekilde L, Danielsen CC, Gasser J 1994 The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 134:2126-2134.
21. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83: 2266-2274.
22. Tashjian AH, Chabner BA 2002 Clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women and men. J Bone Miner Res 17:1151-1161.
23. Ste-Marie L-G, Scheele WH, Jasque-Romano S, Schwartz SL, Clancy AD, Myers SL 2001 Bone mineral density changes during an 18 month observational period following discontinuation of recombinant human parathyroid hormone (1-34) treatment of postmenopausal women receiving hormone replacement therapy. Arthritis Rheum 44(Suppl):S257.
24. Kulkirni PM, Gaich GA, Scheele WH 2001 Lumbar spine bone mineral density response rates in a study of recombinant human parathyroid hormone (1-34) compared to alendronate sodium in postmenopausal women with osteoporosis. Arthritis Rheum 44(Suppl):S379.
25. Orwoll E, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A 2001 Brief therapy with recombinant human parathyroid hormone (1-34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteoporosis. J Bone Miner Res 16:S1;S221.
26. Lindsay R, Scheele WH, Clancy AD, Mitlak B 2001 Incident vertebral fractures during an 18 month observation period following discontinuation of LY333334 [recombinant human parathyroid hormone (1-34), rhPTH (1-34)] use in postmenopausal women with osteoporosis. J Bone Miner Res 16:S1;S163.
27. Palmer M, Adami HO, Krusemo UB, Ljunghall S 1988 Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol 127:1031-1040.
28. Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton LJ III 1998 Survival after the diagnosis of hyperparathyroidism: A population-based study. Am J Med 104: 115-122.